糖尿病黄斑水肿与二极管阈下微脉冲激光(DIAMONDS):随机对照试验研究方案
DIAMONDS是一项多中心、分配隐藏、随机、等效性、双盲临床试验,旨在比较阈下微脉冲激光与标准阈值激光治疗中心视网膜亚区厚度(CST)<400 μm的糖尿病黄斑水肿的临床有效性和成本效果。主要结局为治疗至第24个月研究眼最佳矫正视力较基线的平均变化;统计分析采用符合方案分析,以95%CI比较组间差异与5个ETDRS字母的允许最大差值。
要点
- 比较阈下微脉冲激光与标准阈值激光治疗CST<400 μm糖尿病黄斑水肿的等效性。
- 主要结局为24个月最佳矫正视力变化,等效界值为5个ETDRS字母。
- 采用符合方案分析而非意向性分析,因后者在等效性试验中增加I型错误。
核心结论
- 该试验将确定阈下微脉冲激光相比标准阈值激光治疗糖尿病黄斑水肿的临床有效性和成本效果。
研究设计与样本
- DIAMONDS是一项实用性、多中心、分配隐藏、随机、等效性、双盲临床试验。
- 研究纳入CST<400 μm的糖尿病黄斑水肿患者,比较阈下微脉冲激光与标准阈值激光。
主要发现
- 主要结局为研究眼最佳矫正视力从基线至治疗后第24个月的平均变化。
- 次要结局(24个月)包括双眼最佳矫正视力变化、CST、Humphrey 10-2视野平均偏差、符合驾驶标准人数百分比变化、欧洲五维健康量表、国家眼科研究所视觉功能问卷-25和VisQoL评分、每获得一个质量调整生命年的增量成本、副作用、激光治疗次数及附加治疗使用。
关键数值与推荐
- 主要统计分析采用符合方案分析而非意向性分析,因为后者在非劣效或等效性试验中增加I型错误。
- 使用95%CI比较激光间最佳矫正视力变化的差异与5个ETDRS字母的允许最大差值。
- 采用线性和逻辑回归模型比较治疗组间结局。
- 基于马尔可夫模型的成本效用分析将延伸至试验期外以估计长期成本效果。
临床怎么用
- 该试验结果可为CST<400 μm的糖尿病黄斑水肿患者选择阈下微脉冲激光或标准阈值激光提供临床有效性和成本效果证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the UK, macular laser is the treatment of choice for people with diabetic macular oedema with central retinal subfield thickness (CST) < 400 μm, as per National Institute for Health and Care Excellence guidelines. It remains unclear whether subthreshold micropulse laser is superior and should replace standard threshold laser for the treatment of eligible patients. METHODS: DIAMONDS is a pragmatic, multicentre, allocation-concealed, randomised, equivalence, double-masked clinical trial that aims to determine the clinical effectiveness and cost-effectiveness of subthreshold micropulse laser compared with standard threshold laser, for the treatment of diabetic macular oedema with CST < 400 μm. The primary outcome is the mean change in best-corrected visual acuity in the study eye from baseline to month 24 post treatment. Secondary outcomes (at 24 months) include change in binocular best corrected visual acuity; CST; mean deviation of the Humphrey 10-2 visual field; change in percentage of people meeting driving standards; European Quality of Life-5 Dimensions, National Eye Institute Visual Functioning Questionnaire-25 and VisQoL scores; incremental cost per quality-adjusted life year gained; side effects; number of laser treatments and use of additional therapies. The primary statistical analysis will be per protocol rather than intention-to-treat analysis because the latter increases type I error in non-inferiority or equivalence trials. The difference between lasers for change in best-corrected visual acuity (using 95% CI) will be compared to the permitted maximum difference of five Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Linear and logistic regression models will be used to compare outcomes between treatment groups. A Markov-model-based cost-utility analysis will extend beyond the trial period to estimate longer-term cost-effectiveness. DISCUSSION: This trial will determine the clinical effectiveness and cost-effectiveness of subthreshold micropulse laser, when compared with standard threshold laser, for the treatment of diabetic macular oedema, the main cause of sight loss in people with diabetes mellitus. TRIAL REGISTRATION: International Standard Randomised Controlled Trials, ISRCTN17742985 . Registered on 19 May 2017 (retrospectively registered).
引用
- Lois N, Gardner E, Waugh N, et al. Diabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): study protocol for a randomised controlled trial. Trials. 2019. PMID: 30755274. doi:10.1186/s13063-019-3199-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。